{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["13(2)"],"submitter":["Channick R"],"funding":["Actelion Pharmaceuticals Ltd, a Janssen Pharmaceutical Company of Johnson and Johnson"],"pubmed_abstract":["<h4>Introduction</h4>Data on real-world clinical practice and outcomes of patients with pulmonary arterial hypertension associated with connective tissue disease (CTD-PAH) are scarce. The OPUS/OrPHeUS studies enrolled patients newly initiating macitentan, including those with CTD-PAH. This analysis describes patient characteristics, treatment patterns, outcomes, and safety profiles of patients with CTD-PAH newly initiating macitentan in the US using the OPUS/OrPHeUS combined dataset.<h4>Methods</h4>OPUS was a prospective, US, multicenter, long-term, observational drug registry (April 2014-June 2020). OrPHeUS was a retrospective, US, multicenter medical chart review (October 2013-March 2017). The characteristics, treatment patterns, safety, and outcomes during macitentan treatment of patien"],"journal":["Cardiology and therapy"],"pagination":["315-339"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11093922"],"repository":["biostudies-literature"],"pubmed_title":["Macitentan in Pulmonary Arterial Hypertension Associated with Connective Tissue Disease (CTD-PAH): Real-World Evidence from the Combined OPUS/OrPHeUS Dataset."],"pmcid":["PMC11093922"],"pubmed_authors":["Ong R","Channick R","Lammi MR","Turricchia S","Mitchell L","McLaughlin VV","Chin KM","Zamanian RT","Kim NH"],"additional_accession":[]},"is_claimable":false,"name":"Macitentan in Pulmonary Arterial Hypertension Associated with Connective Tissue Disease (CTD-PAH): Real-World Evidence from the Combined OPUS/OrPHeUS Dataset.","description":"<h4>Introduction</h4>Data on real-world clinical practice and outcomes of patients with pulmonary arterial hypertension associated with connective tissue disease (CTD-PAH) are scarce. The OPUS/OrPHeUS studies enrolled patients newly initiating macitentan, including those with CTD-PAH. This analysis describes patient characteristics, treatment patterns, outcomes, and safety profiles of patients with CTD-PAH newly initiating macitentan in the US using the OPUS/OrPHeUS combined dataset.<h4>Methods</h4>OPUS was a prospective, US, multicenter, long-term, observational drug registry (April 2014-June 2020). OrPHeUS was a retrospective, US, multicenter medical chart review (October 2013-March 2017). The characteristics, treatment patterns, safety, and outcomes during macitentan treatment of patien","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jun","modification":"2026-05-29T09:49:46.431Z","creation":"2026-04-08T04:10:50.457Z"},"accession":"S-EPMC11093922","cross_references":{"pubmed":["38451426"],"doi":["10.1007/s40119-024-00361-w"]}}